Genentech ’s Actemra meets primary and secondary endpoints in Phase III trial for GCA
Genentech has reported positive results from the Phase III GiACTA clinical trial of Actemra (tocilizumab) to treat adults with giant cell arteritis (GCA).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news